Scarica l'app Stockscreener
29.50
0.10%
-0.03
Dopo l'orario di chiusura:
29.46
-0.04
-0.14%
Precedente Chiudi:
$29.53
Aprire:
$28.89
Volume 24 ore:
383.65K
Relative Volume:
5.08
Capitalizzazione di mercato:
$3.04B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+0.00%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$28.77
$30.26
Intervallo di 1 settimana:
$25.06
$30.26
Portata 52W:
$25.06
$30.26
Metsera Inc Stock (MTSR) Company Profile
Confronta MTSR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
29.50 | 3.04B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.23 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Metsera Inc Borsa (MTSR) Ultime notizie
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares - The Manila Times
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters’ Option to - EIN News
Metsera shares leap on strong IPO performance By Investing.com - Investing.com Nigeria
Metsera shares leap on strong IPO performance - MSN
Metsera IPO opens 42% higher - MSN
Metsera hits $2.7 billion valuation as shares surge 42% in Nasdaq debut - MSN
Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs - MSN
Finance Watch: Metsera, Maze Go Public, Bringing 2025 US IPO Total To Three - News & Insights
Metsera hits $2.7 bln valuation as shares surge 42% in Nasdaq debut - Reuters
Metsera (MTSR) Opens At $25.50, IPO Priced At $18 By Investing.com - Investing.com Australia
Metsera Inc (MTSR): GLP-1 Boom Comes to the IPO Market with Explosive Debut - Smartkarma
Metsera and Maze Therapeutics Secure $415M in IPOs, Signaling Strong Start for US Health Care Industry - Hoodline
Metsera (MTSR) Opens At $25.50, IPO Priced At $18 - Investing.com
Metsera sees stock rally 54% following $275M IPO - MSN
Weight-loss drug developer Metsera raises $275 million in US IPO - MSN
Metsera sees stock rally 54% following $275M IPO (MTSR:NASDAQ) - Seeking Alpha
Metsera IPO opens 42% higher By Investing.com - Investing.com Nigeria
Metsera hits $2.7 billion valuation as shares surge 42% in Nasdaq debut -January 31, 2025 at 01:02 pm EST - Marketscreener.com
Metsera Shares Rise Sharply in Nasdaq Debut -January 31, 2025 at 01:03 pm EST - Marketscreener.com
4 Firms Guide Pair Of Biotech IPOs Raising $415M Combined - Law360
Metsera and Maze IPOs look to bring $415M to Nasdaq - BioWorld Online
Obesity-drug maker Metsera posts largest gain as IPOs defy market swoon - MarketWatch
MTSR IPO NewsObesity biotech Metsera offers fewer shares, prices IPO above the range at $18 - Renaissance Capital
Busy day for biotech IPOs as Metsera, Maze go public with offerings totaling nearly $400M - Fierce Biotech
Two more biotechs, Metsera and Maze, cross IPO finish line - pharmaphorum
Metsera and Maze Therapeutics Boost US Health Care IPOs to Record LevelsNews and Statistics - IndexBox, Inc.
Metsera Prices of Initial Public Offering - citybiz
Metsera, Maze raise a combined $415M in IPO double-header - FirstWord Pharma
Metsera, Maze secure combined $415 million in IPOs - BioPharma Dive
MTSRMetsera, Inc. Latest Stock News & Market Updates - StockTitan
Metsera Inc (MTSR): Obesity Drug Biotech Order Book Is "Hot"; Set for Friday IPO Debut - Smartkarma
Metsera Readies $275 Million IPO For Obesity Treatments (Pending:MTSR) - Seeking Alpha
GLP-1RA developer Metsera targets $289m IPO - Pharmaceutical Technology
Three biotechs go public as IPO momentum increases - The Pharma Letter
Obesity drug developer Metsera sets terms for $275M IPO - MSN
Obesity-Focused Metsera Leads Biotech Firms Eyeing IPOs - Law360
Metsera Inc (MTSR): Obesity Drug Company Seeking up to $1.8b IPO Valuation - Smartkarma
Metsera Seeks $289M Raise, $1.78B Valuation in IPO - BioSpace
Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO - MSN
IPO excitement heats up as Metsera targets $1.8B valuation, Aurion joins queue - FirstWord Pharma
Metsera eyes $289M IPO to fund phase 3 weight loss trial - Fierce Biotech
Google Ventures-Backed Biotech Metsera Seeks $292 Million in IPO - Yahoo Finance
Weight-loss drug developer Metsera seeks up to $1.78 billion valuation in US IPO - MSN
Metsera outlines $250M IPO plans as obesity biotech competition rises - Endpoints News
Weight-loss drug developer Metsera reveals wider loss in US IPO filing - MSN
Metsera, Inc. (MTSR): Peeking at the Prospectus for the Next Obesity and Metabolic Diseases Biotech - Smartkarma
2024’s Top 7 VC Raises in Biotech - BioSpace
Obesity drug developer Metsera files for $100M IPO - MSN
Metsera Inc Azioni (MTSR) Dati Finanziari
Non sono disponibili dati finanziari per Metsera Inc (MTSR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Metsera Inc Azioni (MTSR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BERNS PAUL L | Director |
Feb 03 '25 |
Buy |
18.00 |
789,998 |
14,219,964 |
8,313,680 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Feb 03 '25 |
Buy |
18.00 |
2,222,222 |
39,999,996 |
18,503,128 |
1.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):